FDA Grants Soligenix Fast Track Designation for OrbeShieldTM for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)

Princeton, NJ – January 29, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShield™ (oral beclomethasone 17,21-dipropionate or oral BDP) development program for the treatment of GI ARS has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). Soligenix has also previously received Orphan Drug designation from the FDA for oral BDP for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
Continue reading

Advertisements

Tags: , , ,

Categories: Biotechnology

Author:NJ Tech Council

The New Jersey Tech Council helps companies grow and supports the tech, innovation and entrepreneurial ecosystems in the state and region.

NJTC TechWire

Daily updates about the region's most tech savvy companies

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: